80 results about "Cervical cancer screening" patented technology

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.

The invention relates to a cervical exfoliated cell preservative liquid, the preservative liquid comprises the following components with the contents (by weight): 20 percent to 50 percent of alcohols; 15 percent to 50 percent of anti-aggregation reagent; 5 percent to 10 percent of buffer solution; 1 percent to 20 percent of ion strength maintaining reagent; 0.01 percent to 0.5 percent of anti-microbial reagent; 0.1 to 5 percent of mucus dissolving reagent; and 0 to 0.5 percent of cleaning agent. Compared with the prior art, the preservative liquid can not only lead cells to maintain the shape in an in vitro liquid suspension environment, minimize the protein precipitation, dissolve larger protein substances, such as blood and mucus, and reduce the cell aggregation, but can also selectively eliminate or reduce red cells, effectively kill microbes, prevent the activity of reverse transcriptase and retain the integrity of nucleic acids and proteins for facilitating the later analysis; in addition, the preservative liquid can greatly reduce the costs of consumptive materials for the TCT detection, improve the sensitivity and the specificity of the cervical cancer screening and accelerate the promotion and the popularization of the TCT technology in a medical system.

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

Cervical Acid Phosphatase-Papanicolaou Test Kit (CPK) is an assembly of reagents, controls and instructions for visualization of cervical acid phosphatase on smears or monolayers of cervical specimens, and for performing the CAP-PAP Test (CPT). CPT is a single-slide, double-staining method for demonstration of cervical acid phosphatase activity inside abnormal cervical cells on Papanicolaou stained smears, and a set of criteria for using this test for cervical cancer screening. In previous clinical trials this method was found to enable Pap test screeners to improve test sensitivity (detection of abnormal cells) for more than 10% (from 0.8 to 0.9), and to reduce false negative readings (missing abnormal cells) for more than 50% (from 0.1 to 0.02). Due to better accuracy and the low cost, when approved, CPT may begin to replace current technologies for cervical cancer screening. CPK is designed to meet requirements for testing large series of specimens on regular basis-the usual practice in cytopathology laboratories performing the Pap test. CPK brings consistency for staining and interpretation, makes internal and external controls easier, and improves the test accuracy for lower cost, while increases laboratory productivity for less liability.

The present invention relates to an apparatus for cervical cancer screening, comprising one or more light sources aligned with a beginning of a first optical test path and a beginning of a second optical test path, one or more optical detectors aligned with an end of the first optical test path and an end of the second optical test path, and a processor coupled to the one or more light sources and the one or more optical detectors and methods for using the same. The present invention further relates to a method for cervical cancer screening.

The invention discloses a composition and reagent kit for early cervical cancer detection. The composition comprises 3 CpG island regions subjected to high methylation in an EPB41L3 gene and 3 CpG island region amplifying primers subjected to high methylation in a JAM3 gene, 98% or above of different types of cervical cancer can be covered, and detection of polygene polymethylation regions can berealized through a one-pipe reaction and detection. A specific MGB probe and a degenerate closed primer are preferably selected for cooperation, so that sensitivity and accuracy are further increased.The whole detection process is free from wounds, simple and convenient to operate and easy to interpret, universal qPCR equipment can meet detection, a wholly-closed form is adopted in the PCR process, and the possibility of cross-contamination can be avoided; besides, three segments of two markers are detected at the same time, so that the result is more accurate; and all the factors are integrated, so that the composition disclosed by the invention has social promotion properties. Due to high sensitivity of detection, the composition is suitable for non-invasive early cervical cancer screening.

A method and apparatus for personal screening for early signs of cervical cancer is claimed, whereby the user performs daily or almost daily a diagnostic self-check for some other aspect of reproductive health, and the electronic testing for cervical cancer type of tissue aberration is performed automatically in the background. The screening is invisible to the user, causing no anxiety and no discomfort. The user only becomes alerted to the need to see a physician if a preset condition of reproducibility is reached in the background evaluation of the measurement data if the aberrant pattern has been detected consecutively in a preset number of menstrual cycles, the device prompts the woman to see a physician with a view to undergoing a more demanding definitive diagnostic examination such as colposcopy with biopsy. The invention provides the diagnostic screen in a manner that does not cause the discomfort, anguish and anxiety associated with the Pap smear screen of the prior art.

The invention discloses a cervical cancer cell detection kit based on a boron-doped graphene quantum dot and belongs to the field of biological detection. The cervical cancer cell detection kit comprises reagents A, B and C. The reagent A is a boron-doped graphene quantum dot solution, the reagent B is a cerium nitrate solution, and the reagent C is an adenosine triphosphate solution. Alkaline phosphatase is selected for the kit to serve as a detected targeted goal, the boron-doped graphene quantum dot is adopted as a fluorescent probe, alkaline phosphatase on the surfaces of cervical cancer cells is detected quickly and efficiently through a quantum dot fluorescence analysis method, and the kit can be used in the medical field to detect the cervical cancer cells and concentration thereof. The kit has the advantages of being easy to operate, high in detection result accuracy and sensitivity and low in cost and the like.

The invention discloses a clinical decision-making system and method for cervical lesions. The clinical decision-making system comprises: a terminal acquisition module for acquiring case data of a patient; an input conversion module for extracting the case data of the patient and converting into characteristic variables; a data processing module for respectively performing discretization, sparse coding and binarization processing on the characteristic variables; a prediction module for outputting prediction results after the processed characteristic variables are subjected to weight and offsetdimension assignment processing, rectification function relu transformation and softmax regression operation; a conformation and diagnosis module for confirming final clinical diagnosis results and providing true labels for the prediction results; a data center module for receiving and storing all case data of the patient and periodically iterating the prediction module based on all data; and a display module for displaying the prediction results, the diagnosis results and health guidance advice. The clinical decision-making system and method provided by the invention can improve specificityand accuracy of a current cervical cancer screening strategy, and realize big data sharing and integrated network management of cervical cancer screening.

An apparatus and method are provided for sampling the distal tube, fimbria and / or ovary, includes advancing a device into the peritoneal cavity and sampling material on or adjacent to the distal tube, fimbria or ovary.

The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6 / E7 mRNA expression and loss of replication and / or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.

The invention provides an artificial intelligence cervical cancer screening determination method and device. The artificial intelligence cervical cancer screening determination method includes the steps: obtaining first user information; obtaining a first medical record according to the first user information; obtaining pre-diagnosis information of the first user, wherein the pre-diagnosis information includes cervical cancer information; obtaining the menopause date of the user according to the first medical record; determining whether the menopause date satisfies a first predetermined condition; obtaining a first result when the first predetermined condition is satisfied; and determining a second result based on the pre-diagnosis information and the first result, wherein the second result represents the probability of suffering from cervical cancer for the first user. The artificial intelligence cervical cancer screening determination method solves the technical problems that in theprior art, manual detection is required, and many factors that are subject to human influence exist, and the medical data of the patient is fragmented, thus being not conducive to data analysis. The artificial intelligence cervical cancer screening determination method achieves system integration of the patient data, thus being beneficial to management analysis, and the analysis process is completed automatically, without human factors, thus achieving technical effect with higher reliability.

The invention provides a cervical cancer section recognition method which comprises the following steps of performing the pre-training to form a cervical cancer recognition model according to the pre-prepared training sample associated with a cervical cancer section; and further comprises the following steps of acquiring a pathological section image to be recognized; recognizing the pathological section image through the cervical cancer recognition model, and outputting the recognition result, wherein the recognition result comprises the number of the cervical cancer cells in the pathologicalsection image and the positions of the cervical cancer cells in the pathological section image. The method has the beneficial effects that the suspected cervical cancer cells in the cervical cancer image can be quickly positioned, redundant information is effectively reduced, and the workload in the recognition process is reduced; the digital cervical cancer image can be subjected to statistics instead of a traditional artificial visual mode, the artificial diagnosis process is assisted, and the artificial diagnosis efficiency is greatly improved.

Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.

The invention belongs to the technical field of clinical medicine, provides application of Notch1, p16<INK4a> and hTERC genes as screening markers for cervical cancer, and relates to molecular markersfor detecting double or triple genes of cervical precancerous lesion and early diagnosis of the cervical cancer. Patients with cervical disease have no significant symptoms in the early stages of onset, and are easily overlooked and fail to be treated in time, so that the risk of the disease and the difficulty of treatment are increased. It is controversial to use p16<INK4a> protein as a diagnostic screening index for the cervical cancer, and the credibility is not high. The invention provides a set of markers, namely, the application of the Notch1, p16<INK4a> and hTERC genes as the screeningmarkers for the cervical cancer, positive correlation exists between p16<INK4a>, Notch1 and hTERC genes and carcinogenesis of HPV16, and significant positive correlation exists between p16<INK4a> andhTERC genes and the carcinogenesis of the HPV16, and the markers can be used for application of molecular marker reagents for detecting double or triple genes of cervical precancerous lesion and early diagnosis or screening of the cervical cancer.

An artificial intelligence cervical cancer screening system includes at least one user terminal, at least one intelligent hardware detection trolley, at least one hospital terminal, an intelligent management terminal and a data cloud center, the at least one user terminal, at least one intelligent hardware detection platform The car, at least one hospital terminal and the intelligent management terminal are all networked and connected to the data cloud center through the network. The system has high efficiency in seeing a doctor. Patients can make appointments for various examinations and seeing a doctor through the user terminal, which shortens the efficiency of seeing a doctor and saves waiting time for patients. Moreover, this system realizes the sharing and query of all data, which facilitates the patient's experience in seeing a doctor, and also provides patient data for statistical management by the superior health management department.

The invention discloses a cervical cancer screening kit, comprising an optional reagent to detect expression level of SPARCL1 in blood. The invention also discloses the application of the reagent to detect the expression level of SPARCL1 in blood, in the preparation of cervical cancer screening reagents. The cervical cancer screening kit can effectively judge the risk of people under test to suffer cercal cancer by detecting the expression level of SPARCL1, is applicable to the clinical assisted diagnosis of cervical cancer, provides effective basis for taking related treatment measures or making decisions for patients, and has a good clinical application prospect.

The invention relates to a cervical cancer precancerous lesion screening method combining spectrums and images, and belongs to the field of spectral analysis and medical image processing. The method comprises the following steps: constructing a database according to spectrum and image data collected by a spectrum and endoscope combined probe at the same time, constructing a neural network precancerous lesion classification model by using the spectrum database, displaying the spectral diagnosis results of corresponding detection points on the images of the corresponding detection points by using different colors by utilizing image registration and fusion, reconstructing a precancerous lesion distribution diagram, and outputting the diagnosis results according to the distribution diagram. The method can be independently used as a cervical cancer screening algorithm, and can also provide image guidance for further biopsy. The diagnosis result of the method is the cervical cancer precancerous lesion distribution diagram which is objective and direct and not influenced by the technology of operators.

The invention provides a cervical carcinoma screening method which employs an improved Pap smear for screening. The method comprises the steps: extracting uterine neck secretion, performing conventional staining, film reading and diagnosis; if a patient is diagnosed as ASCUS or a more serious disease by improved Pap smear in cytologic level, performing pathology biopsy under iodine staining inspection. The invention also provides a cervical carcinoma two-method combined screening method. The method comprises: acquiring uterine neck secretion by improved Pap smear, immediately employing an acetic-acid naked-eye inspection method for screening: if a patient is diagnosed as positive by the acetic-acid naked-eye inspection method, performing pathology biopsy at once; and if a patient is diagnosed as negative, waiting for a diagnosis result of the improved Pap smear on site, if the patient is diagnosed as ASCUS or a more serious disease by the improved Pap smear, performing pathology biopsy at once. The methods provided by the invention employ two, but not one, methods for screening on women at the same time, which is not achieved before the methods provided by the invention are disclosed. The methods provided by the invention help to improve detection rate of cervical precancerous lesion and early-stage cancer.

The invention discloses a method of detecting a human papilloma virus 16 / 18 type gene in urine by using digital PCR (polymerase chain reaction). The method comprises the particular steps of extracting DNA (deoxyribonucleic acid) from the urine, preparing a primer reaction solution, preparing a droplet, performing PCR amplification, detecting the droplet, analyzing data and displaying a result, wherein a lysate comprises 10mM of Tris-HCl, 1mM of EDTA (ethylene diamine tetraacetic acid) and 0.5% of SDS (sodium dodecyl sulfonate); a pH (potential of hydrogen) value of a sodium acetate solution is 5.2. The detection mode is free from age limit and available; sampling is noninvasive; the method has high sensitivity and high precision and overcomes the detection difficulty arising from little viral nucleic acid in the urine; HR-HPV detection in the urine can be widely applied to clinical diagnosis and treatment and cervical cancer screening; the method has the advantage that the method has an important significance for prevention and treatment of a cervical cancer.

Point-of-care tools for screening biological samples for markers associated with pathogenic microbial infections. In particular, devices and systems for screening cervical cells for the expression of proteins, which occur as a result of human papillomavirus infection and progression to invasive cervical cancer.

The invention discloses a method for ovarian cancer screening based on an ovarian cancer marker and a logic gate operation, and belongs to the technical field of biomedicine. The protein-nucleic acidrecognition technology, the signal amplification technology and a logic gate are combined, aptamers of CEA and CA125 are used for target recognition, signal transformation and amplification are performed through a G-quadruplex-heme complex, and a method for simultaneous detection of tumor markers is established. According to the method, an optical biosensor with high sensitivity and strong specificity is constructed for achieving the joint detection of the CEA and the CA125, and an ovarian cancer screening result is provided based on the logic gate; through the combination of optical detectionand the signal amplification technology, the detection sensitivity is improved; the universality of the detection principle makes the method also suitable for detection of different objects based ondifferent protein recognition elements.

The invention discloses a rapid cervical cancer screening system and method. The system comprises a handheld device and a host in communication connection with the handheld device. The handheld deviceis provided with a first electrode pair used as excitation electrodes to generate current signals, a second electrode pair used as measuring electrodes to detect impedance, a light source and a detector. The host comprises a control module and a data processing module, the control module is used for controlling the handheld device, and the data processing module is used for processing detection data of the handheld device to obtain a detection result. According to the method, normal cervical tissues are distinguished from cancerous cervical tissues by detecting the difference of the normal cervical tissue and the cancerous cervical tissue in electrical and optical properties. According to the invention, electrical detection is conducted on the cervical tissue, optical detection is combined to serve as compensation, rapid screening of cervical cancer can be achieved according to the difference of electrical and optical characteristics of normal cervical tissue and abnormal cervical tissue, and the accuracy of diagnosis results can be improved.

The invention belongs to the technical field of immunology, and particularly relates to a household cervical cancer screening reagent card which comprises a bottom plate, a sample pad, a latex combination pad, a nitrocellulose membrane and an absorption pad, detection lines and a quality control line are arranged on the nitrocellulose membrane, the detection lines comprise a p16 detection line and a ki-67 detection line, and the quality control line comprises a quality control line and a quality control line. The p16 detection line, the ki-67 detection line and the quality control line are parallel to one another, and the p16 detection line and the ki-67 detection line are respectively obtained by spraying a solution of a p16-point membrane antibody and a solution of a ki-67-point membrane antibody on the nitrocellulose membrane. According to the household cervical cancer screening reagent card, the p16 point membrane antibody and the ki-67 point membrane antibody are adopted to obtain the p16 detection line and the ki-67 detection line respectively, detection results of the two detection lines are combined and analyzed, various physical conditions can be evaluated, the detection accuracy is improved, in addition, the reagent card is simple in using method, and the results are simple and easy to understand.

The invention belongs to the technical field of medical devices, and discloses a cervical lesion detector which comprises a pressure power device and a detection bar. The pressure power device comprises a holding body, a base hole is formed in the front end of the holding body, a transmission sleeve is arranged in the base hole and rotates relative to the base hole, a wireless pressure sensor is arranged at the bottom of the transmission sleeve, a motor and a main board are arranged in the holding body, the motor is used for driving the transmission sleeve, the main board is used for controlling the motor to run, the detection bar comprises a detection shaft matched with the transmission sleeve, a conical detection head is arranged at the front end of the detection shaft, the rear end of the detection shaft can be inserted into a sleeve, and the pressure is applied to the wireless pressure sensor. According to the detector, a clinician can independently judge and read a result in cervical lesions detection, and the detector is bedside, easy to operate, low in cost, short in time and suitable for popularization and use and solves awkward situations in domestic cervical cancer screening of women.

The invention discloses a primer combination, a probe combination and a human papilloma virus nucleic acid detection kit. The invention relates to the field of biological detection, in particular to aPCR fluorescent probe detection method for diagnosing high-risk human papilloma virus infection, which comprises the following steps: extracting human papilloma virus nucleic acid in cervical exfoliated cells by using a paramagnetic particle method, and carrying out real-time fluorescence polymerase chain reaction to obtain the high-risk human papilloma virus detection kit to detect 14 HPV DNA types in the sample and typing the HPV 16 / 18; and meanwhile, carrying out female cervical cancer screening in combination with cytological examination. The kit can be used for qualitative detection of high-risk human papilloma viruses in cervical cell samples of patients, and typing identification of HPV16 and HPV18 types is realized while HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 are detected. The kit is used for qualitatively detecting high-risk HPV DNA in cervical cells of a patient and determining whether the patient needs colposcope examination or not.

The invention discloses a methylation site for cervical cancer screening. The methylation site is a cg24575234 site of a CHRM2 gene, a cg06818777 site of a CHAD gene, a cg08361126 site of an FGF10 gene, and a cg08976810 site of an ITGA8 gene. The invention also discloses a primer pair included in a kit for detecting a methylation level of a sample gene of cervical cancer. According to the invention, a whole process can be automated, the result is objective and is easy to interpret, and the influence of subjective factors is avoided; and the specificity of the methylation site, provided by theinvention, for detecting and screening cervical cancer is 100%, which is greater than the specificity (80%) of an HPV gene detection method, and the positive prediction value is increased from 0.0474%to 100%, so that the screening result is objective and is easy to interpret. The methylation site provided by the invention can also be used in parallel with a current cervical cancer screening experiment, thereby greatly saving the examination cost and avoiding economic losses and psychological burdens of too many false positive patients due to positive results.

The invention relates to the technical fields of genetic engineering and medical detection, and provides a methylated EphA7 nucleotide fragment as a specific diagnosis marker of cervical cancer, and aprimer set, a probe and a reagent kit relevant with the methylated EphA7 nucleotide fragment, and an application of the methylated EphA7 nucleotide fragment to preparation of a cervical cancer screening and diagnosing preparation. The inventor finds that the methylation degree of a promoter region of EphA7 genes in cervical tissues is in significant correlation with the generation of the cervicalcancer, and the methylated EphA7 nucleotide fragment can be used as a biology marker for assisting in diagnosis of the cervical cancer, so that the human cervical cancer can be timely screened and diagnosed for early stage, and the waste of medical resources is avoided.

The invention discloses application of prescriptions composed of vitamin C and baicalein in cervical cancer treatment. A plurality dosages of baicalein and vitamin C form different prescriptions, and the prescriptions are compared with corresponding dosage of single baicalein and single vitamin C and act on U14 cervical cancer tumor-bearing mouse models and HeLa cells. Animal experiments show that the prescriptions composed of the vitamin C and the baicalein are better in tumor inhibiting effect and smaller in toxic and side effects as compared with single vitamin C and single baicalein. Cell experiment results show that when same medicine dosage acts on cells for 12 hours, the cells in prescription groups start to atrophy and deform, and the number of cells is reduced; when the same medicine dosage acts on the cells for 36 hours, cell structures disappear, most cells die, and the inhibiting effect of the prescription groups is evidently better than that of the single vitamin C and single baicalein groups. Therefore, the prescriptions composed of the vitamin C and the baicalein is applicable to cervical cancer treatment.